Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Litronesib

Next Previous
Drug Profile

Litronesib

Alternative Names: KF 89617; LY 2523355

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyowa Hakko
  • Developer Eli Lilly and Company; Kyowa Hakko
  • Class Amides; Antineoplastics; Small molecules; Thiadiazoles
  • Mechanism of Action KIF11 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Leukaemia; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Small cell lung cancer; Solid tumours

Most Recent Events

  • 26 Apr 2013 Discontinued - Phase-I for Leukaemia (acute leukaemia) in USA (IV)
  • 26 Apr 2013 Discontinued - Phase-I for Solid tumours (late-stage disease, metastatic disease) in Japan (IV)
  • 26 Apr 2013 Discontinued - Phase-II for Breast cancer (metastatic disease) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top